Evoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Up 288.5% in October

Evoke Pharma, Inc. (NASDAQ:EVOK) was the recipient of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 101,000 shares, an increase of 288.5% from the October 15th total of 26,000 shares. Based on an average daily trading volume, of 423,900 shares, the days-to-cover ratio is currently 0.2 days. Currently, 7.4% of the company’s shares are sold short.

Evoke Pharma Trading Down 14.8 %

NASDAQ EVOK traded down $0.74 on Wednesday, hitting $4.26. 175,744 shares of the company’s stock traded hands, compared to its average volume of 129,101. The firm has a market capitalization of $3.49 million, a PE ratio of -0.41 and a beta of 0.36. The firm’s 50-day moving average price is $5.08 and its two-hundred day moving average price is $5.52. Evoke Pharma has a 1-year low of $3.54 and a 1-year high of $17.88.

Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). The firm had revenue of $2.55 million during the quarter. Evoke Pharma had a negative net margin of 71.32% and a negative return on equity of 308.49%.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on Evoke Pharma in a research report on Tuesday. They set a “sell” rating on the stock.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.